VEGFA and neoplasm: The standard care for advanced or metastatic ccRCC patients, when nephrectomy is not efficient enough, is to use anti-angiogenic therapies aimed to hinder blood supply for the tumor, mainly by the administration of anti-VEGF-A monoclonal antibody Bevacizumab [36].